Home › Research › Disease mechanisms
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease
Erika N. Cline, Daniel Antwi‐Berko, Karen L. Sundell, Elizabeth A. Johnson, Maddelyn Hyland, Hao Zhang, Hugo Vanderstichele, June M. Kaplow et al.. The Journal of Prevention of Alzheimer s Disease, 2025-02-17
Topic: Amyloid, tau and blood-test diagnosis
and neurogranin changes correlated with sabirnetug-AβO target engagement (p ≤ 0.01). Decreases in tTau, VAMP2, and neurogranin correlated with exposure duration (p ≤ 0.007). Plasma pTau181, pTau217, GFAP, and NfL trended lower. Following three sabirnetug doses, changes in CSF and plasma biomarkers were observed. The CSF biomarker response increased with increasing dose and exposure duration, consistent with previous reports that sabirnetug reaches the central compartment and engages its AβO target. The ongoing phase 2 ALTITUDE-AD study (NCT06335173) will test whether sabirnetug's pharmacodynamic effects can be substantiated with a larger sample size and longer treatment duration.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cline, E. N., Antwi‐Berko, D., Sundell, K. L., Johnson, E. A., Hyland, M., Zhang, H., et al. (2025). Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2025.100082
Vancouver
Cline EN, Antwi‐Berko D, Sundell KL, Johnson EA, Hyland M, Zhang H, et al. Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2025.100082. PMID: 39955261.
BibTeX
@article{cline2025-39955261,
author = {Cline, Erika N. and Antwi‐Berko, Daniel and Sundell, Karen L. and Johnson, Elizabeth A. and Hyland, Maddelyn and Zhang, Hao and Vanderstichele, Hugo and Kaplow, June M. and others},
title = {{Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease}},
journal = {The Journal of Prevention of Alzheimer s Disease},
year = {2025},
doi = {10.1016/j.tjpad.2025.100082},
pmid = {39955261},
url = {https://doi.org/10.1016/j.tjpad.2025.100082}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- and neurogranin changes correlated with sabirnetug-AβO target engagement (p ≤ 0.01).
- Decreases in tTau, VAMP2, and neurogranin correlated with exposure duration (p ≤ 0.007).
- Plasma pTau181, pTau217, GFAP, and NfL trended lower.
- Following three sabirnetug doses, changes in CSF and plasma biomarkers were observed.
- The CSF biomarker response increased with increasing dose and exposure duration, consistent with previous reports that sabirnetug reaches the central compartment and engages its AβO target.
Why it matters
In this phase 1 trial, three doses of sabirnetug were followed by changes in cerebrospinal fluid and plasma biomarkers that increased with dose and exposure duration. The study was small and early, and a larger phase 2 trial is planned to test whether these effects hold up.
Study details
- Study designclinical trial
- Evidence strengthHigh
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Jasna Jerecı̀ć: h-index 11 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Amsterdam University Medical Centers: institution h-index 677 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39955261) |
| Free to read | 2 / 2 | Free to read |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2025.100082
- PubMed: 39955261
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disease mechanisms
Also tagged “cerebrospinal”
821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.